UPDATE: Jefferies Assumes Coverage on Sequenom at Buy on Unappreciated Value

In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on Sequenom (NASDAQ: SQNM ) with a Buy rating, but lowered the price target from $7.50 to $6.00. In the report, Jefferies noted, “SQNM's flagship MaterniT21 test continues to ramp at a blistering clip, formal reimbursement contracts are building,